Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Impact of GPRC5D-targeted therapies on healthcare resource utilization.
Comparing dosing and management strategies for BCMA and non-BCMA bispecific antibodies.
TRIMM-2 Study: Combining Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Current strategies for frontline therapy in transplant-preferred newly diagnosed multiple myeloma.
Managing bispecific adverse events in community settings for myeloma patients.
Managing toxicities after BCMA-directed immunotherapy in myeloma treatment.
Dr. Dhakal reviews key multiple myeloma trials presented in 2024.
TRIMM-2 Study: Bispecific Antibody Combinations in Relapsed/Refractory Multiple Myeloma
Dr. Badros discusses AURIGA study design: Daratumumab/Lenalidomide for newly diagnosed myeloma.
BCMA serum offers monitoring advantages over conventional biomarkers.
Dr. Delforge discusses the efficacy of Cilta-Cel in lenalidomide-refractory myeloma.
Impact of GPRC5D-targeted therapies on healthcare resource utilization examined.
BCMA levels shown to predict multiple myeloma risk, severity, and treatment response.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
Impact of GPRC5D-targeted therapies on healthcare resource utilization.
Comparing dosing and management strategies for BCMA and non-BCMA bispecific antibodies.
TRIMM-2 Study: Combining Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
Current strategies for frontline therapy in transplant-preferred newly diagnosed multiple myeloma.
Managing bispecific adverse events in community settings for myeloma patients.
Managing toxicities after BCMA-directed immunotherapy in myeloma treatment.
Dr. Dhakal reviews key multiple myeloma trials presented in 2024.
TRIMM-2 Study: Bispecific Antibody Combinations in Relapsed/Refractory Multiple Myeloma
Dr. Badros discusses AURIGA study design: Daratumumab/Lenalidomide for newly diagnosed myeloma.
BCMA serum offers monitoring advantages over conventional biomarkers.
Dr. Delforge discusses the efficacy of Cilta-Cel in lenalidomide-refractory myeloma.
Impact of GPRC5D-targeted therapies on healthcare resource utilization examined.
BCMA levels shown to predict multiple myeloma risk, severity, and treatment response.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
